3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
2
Cyclophosphamide
2
Cisplatin
2
sargramostim
1
regorafenib
1
fludarabine
1
entinostat
1
durvalumab
1
cemiplimab
1
avelumab
1
atezolizumab
1
abemaciclib
1
Surgical Procedures, Operative
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Platinum
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Midazolam
1
Microarray Analysis
1
Megestrol Acetate
1
Levoleucovorin
1
Leucovorin
1
Letrozole
1
LY3023414
1
Interleukin-2
1
Interferon-gamma
1
Interferon-alpha
1
Immunoenzyme Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Blood Component Removal
×
Breast
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled